|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 7/04 | (2006.01) |
| C12N 15/863 | (2006.01) | ||
| C07K 14/07 | (2006.01) | ||
| A61K 35/76 | (2006.01) | ||
| A61K 39/285 | (2006.01) | ||
| A61K 48/00 | (2006.01) |
| (11) | Number of the document | 2202297 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10003287.9 |
| Date of filing the European patent application | 2008-07-18 | |
| (97) | Date of publication of the European application | 2010-06-30 |
| (45) | Date of publication and mention of the grant of the patent | 2014-05-14 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 950587 P | 2007-07-18 | US | |
| 981748 P | 2007-10-22 | US |
| (72) |
Szalay, Aladar A., US
Chen, Nanhai, US
Yu, Yong A., US
|
| (73) |
Genelux Corporation,
3030 Bunker Hill Steet, Suite 310, San Diego, California 92109,
US
|
| (54) | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |